Search

everythinglearnresearchcommunity

for

Search:↓

A 39 year old female who has been taking finasteride for 1.5 months and is experiencing side effects such as muscle and butt shrinkage, and weight loss despite still having tight clothing. The user is seeking advice from those with knowledge of bodybuilding and hormones to help figure out the issue.

The conversation is about the availability of Breezula, a hair loss treatment, with speculation it might be released in 2022 or potentially never, as it's more effective than finasteride. No specific treatments were confirmed.

Minoxidil bottle developed crystals, possibly due to air exposure, but the trichologist advised not to worry. The user questions the advice, noting the lack of recommendations for finasteride or derma rolling.

A user shared their experience with hair loss treatments, including oral and topical finasteride, minoxidil, and Nutrafol, experiencing side effects like erectile dysfunction and reduced libido. They are considering adjusting their treatment plan and exploring other options like dutasteride, oral minoxidil, or a hair system.

The user is considering adding liposomal dutasteride to their hair loss treatment, which currently includes topical finasteride and minoxidil. They are exploring different concentrations and application frequencies to enhance hair retention and are also planning to continue using Rogaine.

The user is concerned about mixing Pantostin (with Alfatradiol) and Finasteride in a topical solution, fearing a potential toxic reaction or ineffectiveness. They seek advice on whether this combination is safe.

The potential of using a specific antibody, HMI-115, as a treatment for hair loss alongside traditional treatments such as minoxidil and finasteride. The user suggests trying either a 240 mg or 30 mg dose to see if it works.

The user expresses positivity about managing hair loss and celebrates good hair days. They mention using finasteride (Propecia) as part of their treatment.

Fluridil was abandoned due to its weak effectiveness and low binding affinity to the androgen receptor, making it less competitive against DHT and testosterone. Users discuss its limited results compared to other treatments like pyrilutamide and RU58841.

The conversation critiques the influence of "Clavicular" on young men regarding hair loss treatments, highlighting the dangers of following unscientific advice and the rise of body dysmorphia. It emphasizes the importance of safe, medically advised treatments like minoxidil, finasteride, and dutasteride, while warning against reckless experimentation and early surgeries.

The conversation discusses starting finasteride for hair loss, addressing concerns about side effects, dosage, and travel with the medication. It suggests taking the pill without overthinking side effects and reassures that carrying it on a plane is generally not an issue.

The conversation is about the claim that oral minoxidil can make hair grow on bones. The conclusion is that this claim is not true, as evidenced by the user's head being bald while the body is furry.

The conversation discusses a product called Rexagain Mixprocapil, which includes topical finasteride. Users express skepticism about the product's legitimacy and caution about its use.

A user decided to stop using finasteride due to side effects and chose to shave their head instead. They plan to use the money saved for a hair transplant towards a house downpayment, hoping for future advancements in hair cloning.

The user is frustrated with ongoing hair loss despite using treatments like finasteride, dutasteride, minoxidil, RU58841, and others. They express concern over the lack of improvement in hair density and the emotional toll it takes.

Finasteride is commonly used for hair loss, with mixed experiences regarding sexual side effects. Some users report no issues, while others experience difficulties, but many find increased confidence and libido.

Kintor 0.9% is not effective for hair regrowth or thickening and may cause testicle sensitivity. The conversation criticizes the hype around Kintor and discusses the ineffectiveness of pyrilutamide compared to other treatments like RU58841, finasteride, and minoxidil.

The conversation discusses the use of RU58841, a non-FDA approved research chemical for hair loss, with mixed opinions on its safety and effectiveness. Some users are willing to try it as a last resort after other treatments like Minoxidil and Finasteride failed, while others express concerns about potential long-term side effects and lack of official research.

Kevin Mann avoids dutasteride because it comes in gelatin capsules, which he avoids as a vegan, and he is satisfied with finasteride's results. He prefers finasteride due to more long-term research and follows the principle of "if it ain't broke, don't fix it."

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

A user who has tried multiple treatments for hair loss, including oral and topical finasteride and liposomal finasteride, but experienced severe side effects in each case; the user is considering trying RU58841 or aromatise inhibitors as alternatives.

PP405 is seen as promising but uncertain, with users advised to continue using existing treatments like minoxidil and finasteride. Concerns include its cost, availability, and interaction with hair transplants, while some hope it could complement current treatments.

A person is struggling with hair loss and mental health issues, using treatments like dutasteride and minoxidil, and planning a hair transplant. They recently discovered their biological father is bald, causing additional stress, but are encouraged by others to focus on their treatment success and seek professional help for their mental health.

Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

The conversation discusses using finasteride for 2 years and dutasteride for 6 months to treat hair loss, resulting in significant improvement. The user did not experience side effects and did not use other treatments like minoxidil, supplements, or micro-needling.

A user switched from finasteride to Avodart (dutasteride) due to the ineffectiveness and poor quality of finasteride in their country. They advise others in similar situations to seek original brands.

Dutasteride and finasteride may temporarily affect semen quality but are unlikely to cause permanent infertility. The Kim et al. study is criticized for poor methodology, and many prefer hair retention over potential fertility concerns, using treatments like dutasteride, finasteride, and minoxidil.

OP is seeking recommendations for thickening tonics and decides to try Aveda thickening tonic after a suggestion. Another user recommends hair powder as an alternative.

OP used oral minoxidil (2.5 mg) and dutasteride (0.5 mg) for 12 months with successful hair regrowth. Consistency in treatment is emphasized, and switching from finasteride to dutasteride is suggested for better results.